Phelinun Den europeiske union - tsjekkisk - EMA (European Medicines Agency)

phelinun

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastická činidla - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.

ALKERAN 2MG Potahovaná tableta Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

alkeran 2mg potahovaná tableta

aspen pharma trading limited, dublin array - 1571 melfalan - potahovaná tableta - 2mg - melfalan

ALKERAN 50MG Prášek a rozpouštědlo pro injekční/infuzní roztok Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

alkeran 50mg prášek a rozpouštědlo pro injekční/infuzní roztok

aspen pharma trading limited, dublin array - 1571 melfalan - prášek a rozpouštědlo pro injekční/infuzní roztok - 50mg - melfalan

LENALIDOMID ZENTIVA 10MG Tvrdá tobolka Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

lenalidomid zentiva 10mg tvrdá tobolka

zentiva, k.s., praha array - 17180 lenalidomid - tvrdá tobolka - 10mg - lenalidomid

LENALIDOMID ZENTIVA 15MG Tvrdá tobolka Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

lenalidomid zentiva 15mg tvrdá tobolka

zentiva, k.s., praha array - 17180 lenalidomid - tvrdá tobolka - 15mg - lenalidomid

LENALIDOMID ZENTIVA 25MG Tvrdá tobolka Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

lenalidomid zentiva 25mg tvrdá tobolka

zentiva, k.s., praha array - 17180 lenalidomid - tvrdá tobolka - 25mg - lenalidomid

LENALIDOMID ZENTIVA 5MG Tvrdá tobolka Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

lenalidomid zentiva 5mg tvrdá tobolka

zentiva, k.s., praha array - 17180 lenalidomid - tvrdá tobolka - 5mg - lenalidomid

Brukinsa Den europeiske union - tsjekkisk - EMA (European Medicines Agency)

brukinsa

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastická činidla - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Lunsumio Den europeiske union - tsjekkisk - EMA (European Medicines Agency)

lunsumio

roche registration gmbh - mosunetuzumab - lymfom, folikulární - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.

Carvykti Den europeiske union - tsjekkisk - EMA (European Medicines Agency)

carvykti

janssen-cilag international nv - ciltacabtagene autoleucel - mnohočetný myelom - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.